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Human papilloma virus (HPV) vaccine coverage in girls 
and women has been dropping markedly in some coun-
tries [1, 2]. In Denmark, first-dose coverage of the HPV 
vaccine dropped from around 80% in 2014 to 45% in 
2016 [3]. Concern about the presumed side effects is 
the commonest reason why [4]. It is estimated that 
more than 0.5 mill Danish girls and women had re-
ceived HPV vaccination by the end of 2015 [5]. A re-
port from the Danish Health and Medicines Authority 
in 2015 showed  a total of 1,305 reported side effects to 
the HPV vaccine, including 363 that were assessed as 
serious [5]. Consequently, many researchers have at-
tempted to determine whether the reported side effects 
have any association with the HPV vaccine [6-10]. The 
majority of the studies show no causal relation, and any 
association remains unverified [11]. However, despite 
lack of evidence, still fewer girls and women opt for the 
vaccination [1]. 
The most frequently reported side effects are injec-
tion-site reactions, headache and fatigue [8]. However, 
we also noted reports of sleep-related symptoms such 
as excessive daytime sleepiness, dream activity and  
periods of muscle weakness. These symptoms are com-
monly seen in individuals with narcolepsy type 1 [12]. 
This led us to speculate whether HPV vaccination could 
be associated with the development of narcolepsy type 
1. narcolepsy type 1 is a chronic neurological sleep dis-
order caused by hypocretin deficiency, which is likely 
due to autoimmune destruction of hypothalamic hypo-
cretinergic neurons [12, 13]. The core symptoms of 
narcolepsy are excessive daytime sleepiness and signs 
of rapid eye movement (REM)-sleep dissociation, the 
most specific being cataplexy. Cataplexy is defined as 
more than one episode of generally brief (< 2 min.), 
usually bilateral symmetrical sudden loss of muscle 
tone with retained consciousness [12, 14]. The devel-
opment of narcolepsy type 1 has previously been asso-
ciated with another specific vaccine preparation: the 
Pandemrix H1N1 vaccine [15, 16]. The other variant of 
narcolepsy – narcolepsy type 2 – is characterised by 
normal cerebrospinal fluid; as such there is no loss of 
hypocretinergic neurons and it is not believed to have 
an immune system-related pathogenesis. For this rea-
son, we did not include this or any other sleep dis orders 
in the analysis.
We here aimed to evaluate whether sleep-related 
symptoms following HPV vaccination could be associ-
ated with development of narcolepsy type 1.  There-
fore, we conducted a retrospective case-series study of 
HPV-vaccinated individuals with specific sleep com-
plaints. 
METHODS
We evaluated 29 girls and women with self-reported 
sleep complaints after HPV vaccination in a retrospect-
ive study. At the time, the Syncope Unit at Bispebjerg-
Frederiksberg Hospital was the National Centre for 
HPV vaccine side-effect in Denmark. The Syncope Unit 
received the majority of references regarding suspected 
side effect to the vaccine that were of a degree that re-
quired assessment at a hospital department. By the end 
ABSTRACT
INTRODUCTION: Human papilloma virus (HPV) vaccine 
uptake in girls and women is dropping markedly in some 
countries. Concern about the presumed side effects is the 
commonest reason why. Reports about side effects include 
specific sleep complaints such as excessive daytime 
sleepiness, altered dream activity and periods of muscle 
weakness. These symptoms are commonly seen in 
individuals with narcolepsy type 1. We aimed to evaluate 
whether HPV vaccination was associated with the 
development of hypocretin-deficient narcolepsy.  
METHODS: We report the evaluation for sleep disorders, 
including narcolepsy, in 29 HPV-vaccinated girls and women 
who were submitted for evaluation of narcolepsy. All were 
evaluated by polysomnography and the Multiple Sleep 
Latency Test, and 18 individuals were also evaluated by 
measures of cerebrospinal fluid hypocretin-1 concentration. 
RESULTS: None of the 29 girls and women showed signs of 
narcolepsy type 1.  
CONCLUSION: Our results do not suggest that an 
association exists between HPV vaccination and the 
development of narcolepsy type 1. 
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of the summer of 2015, more than 600 girls and 
women had been evaluated at the clinic. Some of them 
had specific sleep complaints: self-reported fatigue, 
sleepiness, increased dream activity, fragmented sleep 
and periodic muscle weakness. Thus, in the period 
from June 2015 to November 2015, the girls and 
women with sleep complaints were selected. Out of 
187 girls and women evaluated for suspected side ef-
fects in this period, 29 had specific sleep complaints. 
These girls and women were clinically referred to the 
Danish Centre for Sleep Medicine (DCSM) for sleep 
evaluation on these criteria. Sleep examinations were 
conducted from July to November 2015. All partici-
pants were evaluated with a focused medical interview 
and a neurological examination assessing: sleep habits, 
dream activity, hypnogogic hallucination, sleep paraly-
sis, cataplexy, fatigue and sleepiness including the Ep-
worth sleepiness scale. Further, they were examined 
with polysomnography (PSG), the Multiple Sleep La-
tency Test (MSLT), blood tests and lumbar puncture 
(including HLA-DQB1*06:02, immunoglobulins, cere-
brospinal fluid hypocretin-1 (csf-hcrt-1) level) [17]. 
The PSG and MSLT were done according to the stan-
dard procedure in the clinic [17]. Most of the PSG  
were ambulant, but a few were admitted for the  
PSG for practical reasons, e.g., due to long transport 
time.
The diagnostic criteria for narcolepsy type 1 are ex-
cessive daytime sleepiness for at least three months and 
presence of one or both of the following: 1. Cataplexy 
and a sleep latency (SL) of 8 min. or below and two or 
more Sleep Onset of REM Periods (SOREMPs); 2. A csf-
hcrt-1 concentration below 110 pg/ml [12, 13].  
We evaluated data on subjective sleep complaints 
and from PSG in a retrospective study. All girls and 
women with self-reported sleep complaints were in-
cluded in the study and none were excluded. The study 
was approved by the Danish Health and Medicines 
Authority. 
Trial registration: not relevant.
RESULTS
Characteristics of the 29 girls and women are shown in 
Table 1 including sleep-related symptoms reported at 
medical interview and information about the given 
HPV vaccine. In addition to the sleep-related symp-
toms, all girls and women complained of dizziness and 
26 (89.7%) of general muscles weakness. Finally, 21 
(72.4%) of the girls and women complained of chronic 
headache and 21 (72.4%) of muscle and joint pain. 
One girl did not participate in a medical interview, and 
therefore her symptoms were not characterised. Data 
on the HPV vaccine given were available for 27 of the 
girls and women (Table 1). All the girls and women re-
TABLE 2
Results from polysomnography, the Multiple Sleep Latency Test, 
hypocretin and narcolepsy-associated tissue type.
Polysomnography 
(N = 29)
Total sleep time, h, median (range) 6.9 (4.0-8.9)
Sleep efficiency, %, median (range) 86.8 (48.8-98.1)
Sleep latency, h, median (range) 0.39 (0.00-1.95)
REM latency, h, median (range) 1.17 (0.41-4.42)
Awakenings, n, median (range) 16 (2-66)
Multiple sleep latency test 
(N = 28)
Sleep latency, min., median (range) 14.3 (4.4-20.0)
Sudden onset of REM sleep, n (%)
0/5 sleep periods 15 (53.6)
1/5 sleep periods   9 (32.1)
2/5 sleep periods   3 (10.7)
3/5 sleep periods   1 (3.6)
Cerebrospinal fluid 
(N = 18)
Hypocretin-1 concentration, pg/ml, median (range) 407 (338-454)
Narcolepsy-associated tissue type
Positive for tissue type HLA-DQB1*06:02, n (%) 3 (16.7)
REM = rapid eye movement.
TABLE 1
Characteristics of the girls and women at the time of sleep  
evaluation.
Anthropometric profiles 
(N = 29)
Age, yrs, median (range) 21.5 (12.8-32.5)
BMI, kg/m2, median (range) 20.3 (16.3-30.4)
HPV vaccine 
(N = 27)
Time between 1st HPV vaccine dose and  
polysomnography, yrs, median (range)
4.6 (1.9-7.8)
HPV 6-11-16-18, n (%)
Brand not specified 21 (77.8)
Gardasil   5 (18.5)
Gardasil and Silgard   1 (3.7)
Questionnaire 
(N = 28)
Epworth Sleepiness Scale score, median (range) 13 (0-18)
Sleep-related symptoms, n (%) 
(N = 28)
Fatigue 28 (100)
Fragmented sleep 19 (67.8)
Sleepiness 16 (57.1)
Hypnogogic hallucinations   9 (32.1)
Sleep paralysis   4 (14.2)
Cataplexy   0
HPV = human papilloma virus.
3DANISH MEDICAL JOURNAL
Dan Med J 65/11  November 2018 
ported symptom onset closely related to the time of 
their HPV vaccination. 
The results of the PSGs are shown in Table 2. In 
general, PSG revealed that all girls and women had a 
normal distribution of sleep stages, breathing, sinus 
rhythm and movement pattern. The total sleep time 
(TST) was less than 6 h in seven of the girls and 
women.
Results of the MSLTs are shown in Table 2. In gen-
eral, MSLT were normal in 21 girls and women. We 
found one woman had abnormal changes: 2 SOREMs 
and a SL of 6 min.; the TST was 6.6 h. Minor abnormal-
ities were found in six women: 1) four girls and women 
presented with marginal changes in the MSLT; tree had 
2-3 SOREMs, but a normal SL of 12-18 min., one had 1 
SOREM and a SL of 4 min.; they all had slept more than 
6 h during the preceding PSG; and 2) two girls and 
women had 1 SOREM in the MSLT, with a SL of 8 and 6 
min., respectively. However, they had slept less than 6 h 
during the preceding PSG (5.7 and 5.6 h, respectively). 
One MSLT was invalid and a repeat was refused.  
Csf-hcrt-1 and narcolepsy-associated tissue type 
were evaluated in 18 girls and women. The results are 
shown in Table 2. 
DISCUSSION
We performed a retrospective analysis of HPV-vaccin-
ated girls and women with specific sleep complaints 
evaluated for narcolepsy type 1 in June-November 
2015 at the DCSM. This was a small study of a highly 
selected group – 29 girls and women with specific sleep 
complaints out of 187 evaluated for side effects at the 
Syncope Unit in the same period. None of the HPV-vac-
cinated girls and women fulfilled the criteria for a nar-
colepsy type 1 diagnosis. Despite reports of muscle 
weakness, none reported cataplexy; and csf-hcrt-1  
levels were normal in all of those examined. The study 
was not designed to assess with epidemiological tools 
the prevalence of type 1 narcolepsy in the vaccine 
group compared with the background population. This 
would have been difficult to do for several reasons. Ini-
tially, the vaccination coverage was very high (> 90%), 
causing the unvaccinated control group to be very 
small. Also, such data would be biased due to the low 
prevalence of narcolepsy type 1, the known diagnostic 
delay, and the fact that many patients are never diag-
nosed. Instead, we report data from a highly selected 
group of HPV-vaccinated individuals, who were al-
ready under evaluation for side effects and primarily 
suffered from sleep complaints. If there was any associ-
ation with narcolepsy type 1, one would expect to iden-
tify this association in this particular group of individu-
als. Consequently, we believe that HPV vaccination is 
not associated with narcolepsy type 1. The majority of 
the girls and women’s PSG and MSLT were normal.  
A few girls and women had marginal changes in their 
PSG and MSLT, but they all complained of insomnia in 
the period preceding clinical examination, which is 
likely to produce false-positive results. Further, short 
SL in MSLT and SOREM episodes occur in 5% of gener-
ally healthy girls and women [18], so these findings 
should be interpreted with caution. Of those examined, 
three girls and women (17.6%) were positive for the 
narcolepsy-associated tissue type: HLA-DQB1*06:02. 
This result is in line with the prevalence in the general 
population: 12-38% HLA-DQB1*06:02-positive [12]. 
One participant showed electrophysiological 
changes suggestive of narcolepsytype 1; she reported 
periodic insomnia and excessive daytime sleepiness. 
She did not present with hypnogogic hallucination, 
sleep paralysis or cataplexy. She was positive HLA-
DQB1*06:02, but so are 12-38% of the population. Csf-
hcrt-1 was normal (358 pg/ml). Due to the polysomno-
graphic findings, we kept her as an out-patient in the 
DCSM and repeated the PSG and MSLT in June 2017. 
The examinations were completely normal. Further, at 
follow-up we did two weeks of actigraphy which on  
average showed a total sleep time of 6 h and 22 min. 
per day.  Our assessment is that the abnormal changes 
we found in 2015 were caused by sleep deprivation. 
Follow-up did not raise any suspicion of narcolepsy. 
An increased incidence of narcolepsy type 1 was  
reported after the Pandemrix influenza A (H1N1) vac-
cination campaign, especially in Finland, Sweden, 
Norway and Ireland. We therefore consider it import-
ant to report that none of the HPV-vaccinated individu-
als we examined had narcolepsy type 1. There was, on 
average, a long period (4.6 years) between the time at 
which the girls and women had received the HPV vac-
cine and the time at which their sleep evaluations were 
conducted. They all reported a symptoms onset closely 
related to time of their HPV vaccination; however, 
there could be recall bias due to the generally long  
period. We find it unlikely, though, that the follow-up 
is too short and that they might develop narcolepsy 
type 1 at a later point due to their HPV vaccine. All sub-
jects had normal csf-hcrt-1 levels, and as low csf-hcrt-1 
is highly sensitive and specific to n narcolepsy type 1, 
this clearly demonstrates that there were no individuals 
with narcolepsy type 1 in our cohort.
CONCLUSION
Our results do not suggest that an association exists be-
tween HPV vaccination and the development of narco-
lepsy type 1.
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